Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › FOLFIRINOX

FOLFIRINOX

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of FOLFIRINOX

10 trials tracked of FOLFIRINOX: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 100 citations.

10Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 8 Phase 1 1
  1. Phase 3 Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas Completed · 100 cited
  2. Phase 2 FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer Completed
  3. Phase 2 Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer Completed
  4. Phase 2 Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas Completed
  5. Phase 2 A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients Completed
  6. Phase 2 Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer Completed
Show 4 more trials
  1. Phase 2 A Phase II Study of Neoadjuvant FOLFIRINOX Completed
  2. Phase 2 First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem Completed
  3. Phase 2 A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma Completed
  4. Phase 1 Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Immune classical transcriptomic subtype correlates with superior survival in metastatic pancreatic cancer
Oncology Meta-analysis
Immune classical transcriptomic subtype correlates with superior survival in metastatic pancreatic cancer Transcriptomic Signatures May Help Predict Pancreatic Cancer Outcomes
This retrospective pooled analysis of phase 2 trials evaluates transcriptomic signatures and GemPred status in patients with metastatic panc…
New research suggests that specific genetic markers in pancreatic cancer may help predict how well different chemotherapy treatments will wo…
Oct 10, 2026
Comparative Efficacy of Modified FOLFIRINOX and Gemcitabine plus Nab-paclitaxel in Pancreatic Cancer
Oncology Meta-analysis
Comparative Efficacy of Modified FOLFIRINOX and Gemcitabine plus Nab-paclitaxel in Pancreatic Cancer Comparing Two Main Chemotherapy Options for Patients with Pancreatic Cancer
A meta-analysis of 1,204 patients reveals that gemcitabine plus nab-paclitaxel provides superior survival outcomes compared to modified FOLF…
A large review of over 1,200 patients shows that one common drug combination may offer better survival rates than another.
Frontiers Sep 28, 2026
NALIRIFOX shows no significant difference in overall survival compared to FOLFIRINOX in pancreatic cancer
Oncology Meta-analysis
NALIRIFOX shows no significant difference in overall survival compared to FOLFIRINOX in pancreatic cancer NALIRIFOX Shows Similar Survival Rates to FOLFIRINOX for Pancreatic Cancer
This meta-analysis of reconstructed individual patient data evaluated NALIRIFOX versus FOLFIRINOX and mFOLFIRINOX in treatment-naïve patient…
A new analysis shows NALIRIFOX offers similar survival rates to FOLFIRINOX for advanced pancreatic cancer while having different side effect…
Frontiers Sep 19, 2026
Pertuzumab-based regimens and FOLFIRINOX are cost-effective for specific cancers while neoadjuvant pembrolizumab is not
Drug Pipeline Meta-analysis
Pertuzumab-based regimens and FOLFIRINOX are cost-effective for specific cancers while neoadjuvant pembrolizumab is not New data shows cost-effectiveness of specific cancer drug regimens
This systematic review evaluates the cost-effectiveness of neoadjuvant regimens for breast, bladder, and pancreatic cancers. It finds pertuz…
New research identifies which cancer treatments are cost-effective, helping doctors and patients navigate the high costs of advanced care.
Frontiers Sep 13, 2026
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel
Oncology RCT
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel Trial Shows Biomarker Helps Identify Best Treatment for Pancreatic Cancer
This randomized Phase II trial and training cohort evaluated the MULTIPL biomarker in 160 and 268 patients with metastatic pancreatic ductal…
A new biomarker tool may help doctors choose the most effective chemotherapy for patients with metastatic pancreatic cancer.
medRxiv Aug 28, 2026